At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 223 enrolled
Drug / intervention
mirabegron +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety and Efficacy of Mirabegron as Add-on Therapy in Patients With Overactive Bladder Treated With Solifenacin: A Postmarketing Open-label Study in Japan
In Brief
A Phase 4 clinical trial evaluating mirabegron and solifenacin for Overactive Bladder. Completed, enrolled 223 participants across 5 sites.
Detailed Summary
The purpose of this study was to evaluate the safety and efficacy of mirabegron as add-on therapy in patients with OAB treated with solifenacin.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOveractive Bladder
CountriesJapan
Collaborators--
Timeline
Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2012
First PostedDec 2012
Primary CompletionJul 2013
TodayJul 2026
First PostedDec 7, 2012
Enrollment StartOct 1, 2012
Primary CompletionJul 23, 2013
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 13.6 years ago
Interventions
mirabegrondrug
oral
solifenacindrug
oral